← Back to Search

Behavioural Intervention

Allergy Delabeling Tool for Antibiotic Allergy

N/A
Waitlist Available
Led By James Antoon, MD, PhD
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 1 day of discharge for each encounter
Awards & highlights

Study Summary

This trial will investigate how an allergy label can be safely removed in children, which can improve patient care & reduce healthcare costs.

Who is the study for?
This trial is for children in the hospital with a penicillin allergy label, who are considered low-risk for a true allergy based on standard questions asked when they're admitted. There's no exclusion criteria; however, doctors can choose not to use the decision support tool.Check my eligibility
What is being tested?
The study tests if a clinical decision support (CDS) tool aimed at doctors or one led by pharmacists is better at removing unnecessary penicillin allergy labels from kids' medical records. It measures how often these labels are removed and looks at antibiotic use and hospital stay length.See study design
What are the potential side effects?
Since this trial involves information management rather than direct patient treatment, there aren't typical medication side effects. However, inaccuracies in delabeling could lead to incorrect antibiotic administration.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 1 day of discharge for each encounter
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 1 day of discharge for each encounter for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Allergy Delabeling Performed
Secondary outcome measures
Allergy Label Adjustments in EHR

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Provider-targeted Clinical Decision Support ToolExperimental Treatment1 Intervention
This intervention will provide access to a best-practices alert (BPA) containing the patient's risk-stratification status and a link to the local standard of care protocol, oral amoxicillin challenge order set and written consent form (same resources as used in pharmacist -led electronic health record dashboard). If the provider opts to perform the oral challenge and it is successfully passed, a second BPA will prompt them to update the allergy status in the medical record.
Group II: Pharmacist-led EvaluationActive Control1 Intervention
Patients randomized to the pharmacist-led arm will appear in the pharmacy-penicillin electronic health care dashboard. A pharmacist may, at their discretion and in consultation with the primary care team, perform an allergy risk-stratification and oral challenge in low-risk patients using local standard of care protocol

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
856 Previous Clinical Trials
672,192 Total Patients Enrolled
James Antoon, MD, PhDPrincipal InvestigatorVanderbilt University Medical Center
1 Previous Clinical Trials
20 Total Patients Enrolled

Media Library

Physician-targeted CDS tool for PCN allergy delabeling (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05561777 — N/A
Antibiotic Allergy Research Study Groups: Pharmacist-led Evaluation, Provider-targeted Clinical Decision Support Tool
Antibiotic Allergy Clinical Trial 2023: Physician-targeted CDS tool for PCN allergy delabeling Highlights & Side Effects. Trial Name: NCT05561777 — N/A
Physician-targeted CDS tool for PCN allergy delabeling (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05561777 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this clinical trial currently recruiting participants?

"According to the data published on clinicaltrials.gov, this study is seeking volunteers and was first made available on December 1st 2022 before being amended most recently in February 21st 2023."

Answered by AI

What is the aggregate amount of participants in this experiment?

"Affirmative. According to records hosted on clinicaltrials.gov, this medical trial is currently enrolling participants and was initially posted on December 1st 2022. A total of 230 patient are required for the study at one site, with updates last made February 21st 2023."

Answered by AI
~0 spots leftby Apr 2025